Sign In
Buy TLSA
$1.03
+0.0600 (+6.19%)
At Close: Jul 31, 2026
Tiziana Life Sciences secures funding to advance development of MS and Alzheimer's therapy
08:29am, Thursday, 31'st Oct 2024
Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that it has secured up to $10 million in funding through a registered direct offering. The offering includes an initial investment of approximately $5
Tiziana Life Sciences Announces Registered Direct Offering of up to approximately $10 Million
10:29pm, Wednesday, 30'th Oct 2024
Includes initial funding of approximately $5 million, as well as the option for additional proceeds of approximately $5 million Includes initial funding of approximately $5 million, as well as the opt
Tiziana Life Sciences reports promising preclinical results for novel combination therapy targeting obesity
10:14am, Wednesday, 30'th Oct 2024
Tiziana Life Sciences Ltd (NASDAQ:TLSA) has reported positive results from a preclinical study evaluating the combination of its lead development candidate intranasal foralumab and semaglutide, which
Tiziana Life Sciences awarded $4M to advance Alzheimer's disease research
09:01am, Thursday, 19'th Sep 2024
Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that it has secured a $4 million grant from the National Institutes of Health (NIH) to advance research of nasal anti-CD3 as a treatment for Alzheimer
Tiziana Life Sciences names new chief executive
08:53am, Monday, 19'th Aug 2024
Tiziana Life Sciences Ltd (NASDAQ:TLSA) has announced the appointment of Ivor Elrifi as its CEO, replacing acting CEO Gabriele Cerrone who will remain in his role as executive chairman of the board. T
Tiziana Life Sciences Appoints New Chief Executive Officer
07:00am, Monday, 19'th Aug 2024
NEW YORK, Aug. 19, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies
Tiziana Life Sciences secures FDA Fast Track status for MS therapy intranasal foralumab
09:40am, Wednesday, 24'th Jul 2024
Tiziana Life Sciences Ltd (NASDAQ:TLSA) shares moved higher after the biotechnology firm revealed the US Food and Drug Administration (FDA) has granted Fast Track designation to its intranasal formula
Tiziana Life Sciences Granted FDA Fast Track Designation
07:00am, Wednesday, 24'th Jul 2024
NEW YORK, July 24, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies
Tiziana Life Sciences secures $3.4M in non-dilutive funding
11:34am, Friday, 28'th Jun 2024
Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced it has received non-dilutive funding of $3.4 million which will be used to advance its investigation therapy foralumab. The company highlighted that f
Tiziana Receives $3.4 Million in Non-Dilutive Funding
11:01am, Friday, 28'th Jun 2024
NEW YORK, June 28, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough therapies in neurodegenerat
Tiziana Life Sciences secures FDA approval to dose first patient with moderate Alzheimer's with investigational therapy
08:36am, Wednesday, 26'th Jun 2024
Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that it has won approval from the US Food and Drug Administration under an Expanded Access IND to dose its first patient with moderate Alzheimer's dis
Tiziana Life Sciences to Dose First Patient with Moderate Alzheimer's Disease with Foralumab
07:00am, Wednesday, 26'th Jun 2024
NEW YORK, June 26, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies
Tiziana Life Sciences seeks FDA Fast Track Designation for foralumab in MS treatment
10:05am, Tuesday, 11'th Jun 2024
Tiziana Life Sciences Ltd (NASDAQ:TLSA), said it is seeking Fast Track Designation approval from the US Food and Drug Administration (FDA) for its intranasal foralumab therapy to treat non-active, sec
Tiziana Life Sciences reports qualitative improvement in MS patients treated with lead asset
10:13am, Thursday, 06'th Jun 2024
Tiziana Life Sciences Ltd (NASDAQ:TLSA) has unveiled encouraing results from patients with non-active Secondary Progressive Multiple Sclerosis (na-SPMS) enrolled in its Expanded Access Program who hav
Tiziana Life Sciences seeks funding from ALS Association for intranasal foralumab trial
10:17am, Tuesday, 04'th Jun 2024
Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that it along with its research partners at Mass General Hospital have been invited to apply for a prestigious grant from the ALS Association to fund
